114861-14-2

Basic information

• Product Name: 1,2-O-Isopropylidene-5-O-(t-butyldiphenylsilyl)-alpha-D-xylofuranose
• Synonyms: 1,2-O-Isopropylidene-5-O-(t-butyldiphenylsilyl)-alpha-D-xylofuranose;a-D-Xylofuranose, 5-O-[(1,1-diMethylethyl)diphenylsilyl]-1,2-O-(1-Methylethylidene)-;5-O-(tert-Butyldiphenylsilyl)-1,2-O-isopropylidene-alpha-D-xylofuranose;5-O-[(1,1-dimethylethyl)diphenylsilyl]-1,2-O-isopropylidene-±-D-xylofuranose;1,2-Di-O-isopropylidene-5-O-(t-butyldiphenylsilyl)--D-xylofuranose;(3aR,5R,6S,6aR)-5-(((tert-butyldiphenylsilyl)oxy)methyl)-2,2-dimethyltetrahydrofuro[2,3-d][1,3]dioxol-6-ol(WX191815);5-O-(t-Butyldiphenylsilyl)-1,2-O-isopropylidene-a-D-xylofuranose
• CAS NO: 114861-14-2
• Molecular Formula: C₂₄H₃₂O₅Si
• Molecular Weight: 428.59338
• Mol File: 114861-14-2.mol

Chemical Properties

• Boiling Point: 495.5±45.0 °C(Predicted)
• Appearance: /
• Density: 1.16±0.1 g/cm3(Predicted)
• PKA: 13.17±0.60(Predicted)
• CAS DataBase Reference: 1,2-O-Isopropylidene-5-O-(t-butyldiphenylsilyl)-alpha-D-xylofuranose(CAS DataBase Reference)
• NIST Chemistry Reference: 1,2-O-Isopropylidene-5-O-(t-butyldiphenylsilyl)-alpha-D-xylofuranose(114861-14-2)
• EPA Substance Registry System: 1,2-O-Isopropylidene-5-O-(t-butyldiphenylsilyl)-alpha-D-xylofuranose(114861-14-2)

Safety Data

• Hazardous Substances Data: 114861-14-2(Hazardous Substances Data)

Usage

Molecular Structure

1,2-O-Isopropylidene-5-O-(t-butyldiphenylsilyl)-alpha-D-xylofuranose consists of a xylofuranose ring with an isopropylidene group at the 1 and 2 positions, and a t-butyldiphenylsilyl group at the 5 position.

Complexity

1,2-O-Isopropylidene-5-O-(t-butyldiphenylsilyl)-alpha-D-xylofuranose is highly complex due to its multiple functional groups and the arrangement of atoms within its structure.

Classification

It belongs to the group of xylofuranose derivatives and is a sugar derivative.

Functional Groups

The compound contains an isopropylidene group and a t-butyldiphenylsilyl group.

Usage

It is often used as a protecting group in the synthesis of other organic molecules, particularly in the field of carbohydrate chemistry.

Importance in Chemical Synthesis

The intricate structure and functionality of 1,2-O-Isopropylidene-5-O-(t-butyldiphenylsilyl)-alpha-D-xylofuranose make it a valuable tool for creating diverse and complex organic compounds.

Upstream product

• 2460-44-8 β-D-xylopyranoside 
• 77-76-9 2,2-dimethoxy-propane 
• 58479-61-1 tert-butylchlorodiphenylsilane 
• 58-86-6 D-xylose 
• 67-64-1 acetone 
• 20590-53-8 1,2-O-isopropylidene-5-O-trityl-α-D-xylofuranose 
• 20031-21-4 1,2-O-isopropylidene-α-D-xylose 
• 532-20-7 D-xylofuranose 
• 20881-04-3 1,2:3,5-di-O-isopropylidene-D-xylofuranose 
• 87-72-9 D-Xylose 

Downstream Products

• 213963-74-7 ((3aR,5R,6S,6aR)-6-Benzyloxy-2,2-dimethyl-tetrahydro-furo[2,3-d][1,3]dioxol-5-ylmethoxy)-tert-butyl-diphenyl-silane 
• 130469-49-7 5-O-benzoyl-3-deoxy-3-<(benzoyloxy)methyl>-1,2-di-O-acetyl-β-D-ribofuranose 
• 130469-50-0 6-chloro-9-<5-O-benzoyl-3-deoxy-3-<(benzoyloxy)methyl>-2-O-acetyl-β-D-ribofuranosyl>-9H-purine 
• 286408-85-3 (3aR,5R,6R,6aR)-5-[[(tert-butyldiphenylsilyl)oxy]methyl]-2,2,6-trimethyltetrahydro-2H-furo[2,3-d][1,3]dioxol-6-ol 
• 330469-96-0 [(3aR,5S,6aR)-5-(tert-Butyl-diphenyl-silanyloxymethyl)-2,2-dimethyl-dihydro-furo[2,3-d][1,3]dioxol-(6Z)-ylidene]-acetic acid ethyl ester 
• 179236-11-4 tert-butyl-(2,2-dimethyl-6-methylene-tetrahydro-furo[2,3-d][1,3]dioxol-5-ylmethoxy)-diphenyl-silane 
• 75772-03-1 [(3aR,5S,6R,6aR)-5-(tert-Butyl-diphenyl-silanyloxymethyl)-2,2-dimethyl-tetrahydro-furo[2,3-d][1,3]dioxol-6-yl]-methanol 

Relevant articles and documents

Exploring the purine core of 3′-C-ethynyladenosine (EAdo) in search of novel nucleoside therapeutics

A series of new nucleoside analogues based on a C-3 branched ethynyl sugar derivative as present in 3′-C-ethynylcytidine (ECyd) and -adenosine (EAdo), combined with modified purine bases was synthetized and evaluated against a broad array of viruses and t

Method for synthesizing 3'-methoxy guanosine

The invention discloses a synthesis method of 3'-methoxy guanosine, belonging to the technical field of medicines. The method comprises the following steps: with 1,2-O-isopropylidene-alpha-D-xylofuranose I as an initial raw material, selectively protectin

PRMT5 INHIBITORS

The present invention provides a compound of formula (I) Formula (I) and the pharmaceutically acceptable salts, esters, and prodrugs thereof, are PRMT5 inhibitors. Also provided are methods of making compounds of formula (I), pharmaceutical compositions comprising compounds of formula (I), and methods of using these compounds to treat cancer, sickle cell, and hereditary persistence of foetal hemoglobin (HPFH) mutations.

Synthesis of Terminal Ribose Analogues of Adenosine 5′-Diphosphate Ribose as Probes for the Transient Receptor Potential Cation Channel TRPM2

TRPM2 (transient receptor potential cation channel, subfamily M, member 2) is a nonselective cation channel involved in the response to oxidative stress and in inflammation. Its role in autoimmune and neurodegenerative diseases makes it an attractive pharmacological target. Binding of the nucleotide adenosine 5′-diphosphate ribose (ADPR) to the cytosolic NUDT9 homology (NUDT9H) domain activates the channel. A detailed understanding of how ADPR interacts with the TRPM2 ligand binding domain is lacking, hampering the rational design of modulators, but the terminal ribose of ADPR is known to be essential for activation. To study its role in more detail, we designed synthetic routes to novel analogues of ADPR and 2′-deoxy-ADPR that were modified only by removal of a single hydroxyl group from the terminal ribose. The ADPR analogues were obtained by coupling nucleoside phosphorimidazolides to deoxysugar phosphates. The corresponding C2″-based analogues proved to be unstable. The C1″- and C3″-ADPR analogues were evaluated electrophysiologically by patch-clamp in TRPM2-expressing HEK293 cells. In addition, a compound with all hydroxyl groups of the terminal ribose blocked as its 1″-β-O-methyl-2″,3″-O-isopropylidene derivative was evaluated. Removal of either C1″ or C3″ hydroxyl groups from ADPR resulted in loss of agonist activity. Both these modifications and blocking all three hydroxyl groups resulted in TRPM2 antagonists. Our results demonstrate the critical role of these hydroxyl groups in channel activation.

Computer Modelling and Synthesis of Deoxy and Monohydroxy Analogues of a Ribitylaminouracil Bacterial Metabolite that Potently Activates Human T Cells

5-(2-Oxopropylideneamino)-6-d-ribitylaminouracil (5-OP-RU) is a natural product formed during bacterial synthesis of vitamin B2. It potently activates mucosal associated invariant T (MAIT) cells and has immunomodulatory, inflammatory, and anticancer properties. This highly polar and unstable compound forms a remarkably stable Schiff base with a lysine residue in major histocompatibility complex class I–related protein (MR1) expressed in antigen-presenting cells. Inspired by the importance of the ribityl moiety of 5-OP-RU for binding to both MR1 and the T cell receptor (TCR) on MAIT cells, each OH was removed in silico. DFT calculations and MD simulations revealed a very stable hydrogen bond between the C3′?OH and uracil N1H, which profoundly restricts flexibility and positioning of each ribityl-OH, potentially impacting their interactions with MR1 and TCR. By using deoxygenation strategies and kinetically controlled imine formation, four monodeoxyribityl and four monohydroxyalkyl analogues of 5-OP-RU were synthesised as new tools for probing T cell activation mechanisms.

Modified nucleosides for the treatment of viral infections and abnormal cellular proliferation

The disclosed invention is a composition for and a method of seating a Flaviviridae (including BVDV and HCV), Orthomyxoviridae (including Influenza A and B) or Paramyxoviridae (including RSV) infection, or conditions related to abnormal cellular proliferation, in a host, including animals, and especially humans, using a nucleoside of general formula (I)-(XXIII) or its pharmaceutically acceptable salt or prodrug. This invention also provides an effective process to quantify the viral load, and in particular BVDV, HCV or West Nile Virus load, in a host, using real-time polymerase chain reaction (“RT-PCR”). Additionally, the invention discloses probe molecules that can fluoresce proportionally to the amount of virus present in a sample.

ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF

The invention relates to novel heterocyclic compounds and pharmaceutical preparations thereof. The invention further relates to methods of treating or preventing cancer using the novel heterocyclic compounds of the invention.

CYCLIC DI-NUCLEOTIDE COMPOUNDS AND METHODS OF USE

Disclosed are cyclic-di-nucleotide cGAMP analogs, methods of synthesizing the compounds, pharmaceutical compositions comprising the compounds thereof, and use of compounds and compositions in medical therapy.

3'-SUBSTITUTED METHYL OR ALKYNYL NUCLEOSIDES FOR THE TREATMENT OF HCV

Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either al

A visualizable chain-terminating inhibitor of glycosaminoglycan biosynthesis in developing zebrafish

Heparan sulfate (HS) and chondroitin sulfate (CS) glycosaminoglycans (GAG) are proteoglycan-associated polysaccharides with essential functions in animals. They have been studied extensively by genetic manipulation of biosynthetic enzymes, but chemical to